In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.
|Videos|August 29, 2020
Raj Bhopal Full Interview: COVID-19 Zugzwang
Author(s)Grant M. Gallagher
Bhopal’s recent article, COVID-19 Zugzwang, was published in Public Health in Practice.
Advertisement
Raj Bhopal, CBE DSc, BSc MD, MPH, MBChB, FRCP, FFPHM, is professor emeritus of public health at the University of Edinburgh, Scotland. He held the chair of Public Health in the university until his retirement in 2018.
Bhopal is also the author of Concepts of Epidemiology: Integrating the Ideas, Theories, Principles, and Methods of Epidemiology.
Bhopal’s recent article, COVID-19 zugzwang: Potential public health moves towards population immunity, was published in Public Health in Practice.
Public Health in Practice is an official journal of the Royal Society for Public Health and a sister journal of Public Health.
The article proposes a full suite of COVID-19 interventions.
It also argues, saliently, that scientific inquiry around various SARS-CoV-2 interventions has been frustrated by an unappealing mix of competing ethical priorities societies face, alongside political battles over terms like “herd immunity.”
Dr. Bhopal was also interviewed on the subject by Karan Thapar of The Wire.
The segment covers some of the same topics, but also explores new ones. It can be viewed below.
Advertisement
Related to this article
Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.
Confirmed US measles cases rose 6.8% this week to 5,182, more than double the 2025 total, as three states reported measles-associated deaths.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: November 6, 2026
2
Half of Long COVID Patients Substantially Improve Within 3 years
3
Real-World Data Show Lenacapavir PrEP Reaching New Users
4
Early Metformin Linked to 53% Lower Risk of Long COVID or Death
5